Ocular FIP data sharpen treatment expectations for veterinarians

CURRENT FULL VERSION: Ocular FIP is moving from a frustrating diagnostic endpoint to a condition veterinarians can increasingly treat, but the details still matter. A 2025 case series in the Journal of Veterinary Internal Medicine looked specifically at 20 cats with ocular involvement of feline infectious peritonitis treated with remdesivir, GS-441524, or both, and found that many ocular signs improved during antiviral therapy. For clinicians, that’s notable because published FIP treatment literature has been much stronger on overall survival than on what happens inside the eye. (pmc.ncbi.nlm.nih.gov)

That shift is happening against a broader regulatory and clinical backdrop. In the U.S., the FDA said on May 10, 2024, that although compounded GS-441524 remains an unapproved animal drug and is not technically “legal,” the agency does not intend to enforce approval requirements when veterinarians prescribe it for a specific cat with FIP under the conditions in Guidance for Industry #256. That policy change opened the door to patient-specific compounded access in the U.S. beginning in 2024, bringing veterinarians more directly back into treatment decisions after years in which many pet parents turned to informal or black-market channels. (fda.gov)

The ocular case series helps clarify what success can look like, and where the risks remain. Investigators reported that only one-quarter of cats in the series had both ocular and neurologic disease, which was lower than some clinicians may expect. That matters because ocular and neurologic involvement are often grouped together in treatment discussions, even though ocular disease can present on its own and is seen much more commonly in non-effusive, or dry, FIP than in wet disease. The broader clinical picture is also useful to keep in mind: ocular FIP may be the dominant presenting feature, with anterior segment findings such as keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, and fibrinous exudate, and posterior segment findings including tapetal or non-tapetal retinal lesions, retinal hemorrhage or vascular tortuosity, retinal detachment, and perivascular cuffing. Among cats with follow-up ophthalmic exams, secondary uveitis resolved in 9 of 11 cases, and one enucleated eye showed no histopathologic evidence of active FIP, with feline coronavirus RNA also absent from aqueous humor at the time of removal. At the same time, ocular complications were still clinically important: four of 20 cats presented with glaucoma secondary to uveitis, and two cats that completed antiviral treatment ultimately required unilateral enucleation because glaucoma could not be controlled. (pmc.ncbi.nlm.nih.gov)

The dosing discussion is especially relevant for practice. The authors noted that ocular and neurologic forms of FIP likely require higher doses because of limited penetration across the blood-ocular and blood-brain barriers. In their series, many cats with ocular involvement received 15 to 20 mg/kg of remdesivir or GS-441524 once daily, and the paper also references successful oral GS-441524 protocols in the 10 to 20 mg/kg/day range over 84 days. The authors advised regular tonometry in uveitic eyes and cautioned that systemic anti-inflammatory therapy should be used thoughtfully, particularly in critical patients, after one cat in the series died following suspected gastrointestinal hemorrhage after meloxicam administration. That caution fits with a broader rethinking of FIP protocols: while the traditional course remains 12 weeks, newer work is testing whether higher-dose induction can reduce viral burden faster and whether objective markers such as serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin ratio trends can help determine when treatment can safely stop instead of relying only on clinical improvement. (pmc.ncbi.nlm.nih.gov)

Those findings fit with the larger FIP treatment story. A retrospective study of 307 cats treated with legally sourced veterinary compounded remdesivir and/or GS-441524 reported an 88.6% survival rate, and international guidance from the ABCD now describes oral GS-441524 as the preferred treatment when available, with injectable remdesivir often used for induction in cats that are too sick to tolerate oral medication. The same guidance notes that long-standing 84-day protocols are still common, though shorter-course and dose-optimization work is ongoing. More broadly, clinicians discussing FIP in day-to-day practice increasingly cite response rates in the 85% to 90% range, a striking shift for a disease that was once considered almost uniformly fatal. (pmc.ncbi.nlm.nih.gov)

Industry and clinical commentary has largely centered on access and standardization. AAHA’s reporting on the U.S. launch of compounded GS-441524 highlighted the importance of replacing unregulated sourcing with veterinarian-prescribed, pharmacy-compounded treatment, while Clinician’s Brief framed the new ocular data as an important addition for cases where eye disease is part of the presentation. Educational commentary has also emphasized that FIP diagnosis in practice still remains largely presumptive, built from signalment, clinicopathologic changes, imaging, effusion analysis when present, and compatible ocular or neurologic findings rather than a single easy antemortem test. That doesn’t amount to full consensus on the ideal protocol, but it does show a field moving toward more formalized care pathways, better monitoring, and more realistic client counseling. (aaha.org)

Why it matters: For veterinary teams, ocular FIP is no longer just a marker of poor prognosis. It’s increasingly a treatable presentation, but one that demands careful case selection, dose planning, ophthalmic follow-up, and honest conversations with pet parents about cost, duration, and the possibility of vision-threatening complications even when antiviral therapy is working. The practical takeaway is that antiviral access has improved, the evidence base is getting stronger, and ophthalmic monitoring should be part of the treatment plan rather than an afterthought. (pmc.ncbi.nlm.nih.gov)

What to watch: The next phase will likely focus on prospective studies, clearer dose standards for ocular and neurologic disease, longer-term relapse data, more objective treatment-stop criteria, and whether the U.S. regulatory framework evolves from patient-specific compounded prescribing toward broader, more streamlined access for clinics. (fda.gov)